MediWound Ltd.
MDWDMediWound Ltd. is an Israel-based biopharmaceutical company specializing in the development and commercialization of innovative therapies for burned and wounded skin, including its flagship product, NexoBrid, a new biological enzyme designed for the removal of eschar in burn patients. The company's technologies focus on tissue repair, wound care, and bio-surgical solutions.
Company News
MediWound Ltd. announced it will release Q1 2026 financial results on May 27, 2026, followed by a conference call at 8:30 a.m. ET. The company will discuss results and provide a corporate update on its enzymatic therapeutics pipeline, including FDA-approved NexoBrid® for burn treatment and late-stage EscharEx® for chronic wound debridement.
MediWound announced multiple presentations of new preclinical and clinical data for EscharEx at three major wound care conferences in April and May 2026. The data demonstrates EscharEx's superior debridement mechanism compared to SANTYL, improved scar outcomes, and supports the ongoing Phase III VALUE trial in venous leg ulcers, with planned expa...
The chronic venous insufficiency market is projected to grow from $2.1 billion in 2024 to a larger market by 2034, driven by emerging therapies, medical devices, and increasing prevalence of the condition in aging populations.
MediWound reported a 43% quarterly revenue increase to $5.7 million, improved gross margins, and advanced its Phase III EscharEx trial while establishing strategic partnerships with wound care leaders.
MediWound has initiated a global Phase III trial to evaluate the efficacy and safety of its wound debridement therapy EscharEx for the treatment of venous leg ulcers. The trial aims to assess EscharEx's ability to effectively debride chronic wounds and prepare the wound bed for healing.
